AI Visibility & Share of Voice
LDL-C Lowering Market, Germany
An analysis of 45 brands and 21 molecules. AI Visibility and Share of Voice measured across ChatGPT, Claude, Gemini and Perplexity.
- Ezetimib97%
- Evolocumab88%
- Alirocumab87%
- Inclisiran86%
Intelligence Centre
Independent research.Original benchmarks.Market intelligence.
Evidence-led analysis of how brands, therapies, competitors, messages and sources appear across AI systems — and what the patterns may mean for pharmaceutical strategy.
Benchmarks
Interactive market benchmarks
Click through our interactive dashboards to see how pharma brands compete across AI models. Feel free to use or publish the data with reference to Theralexis.com.
Market-wide and industry-level intelligence
This area publishes independent research, original benchmarks and perspectives on how AI systems represent therapies, brands, evidence and sources across the market. It does not contain organisation-specific assessments or recommendations.
Organisation-specific insights
Theralexis Solutions translate that intelligence into assessments configured around a specific brand, portfolio, market or strategic question — confidential, and separate from anything published here.
Research and perspectives
First publications are in development
Theralexis is preparing evidence-led perspectives on AI representation in pharma. Approved publications will appear here as they become available.
Why Theralexis publishes research and analysis
AI systems are becoming an important layer through which pharmaceutical, therapeutic and scientific information is accessed, summarised and interpreted. Much of the public conversation still focuses on whether these systems are being adopted, rather than on the quality, emphasis and strategic implications of the answers they produce.
The Theralexis Intelligence Centre will examine selected patterns in how brands, therapies, competitors, evidence and sources are represented across AI systems. The aim is to help pharmaceutical leaders recognise broader patterns and understand their potential strategic implications, while client work remains tailored, confidential and configured around a specific question.
Public analysis keeps observed evidence separate from interpretation. Publications share selected findings and their strategic implications; they do not reproduce complete datasets or the proprietary methods behind Theralexis assessments.
Explore a specific question
Discuss how Theralexis could assess a brand, therapy, market or representation question in greater depth.